Aerocrine signs UK & Irish partnership deal with Healthcare 21.

Solna (Sweden) – January 17, 2014 – Aerocrine AB (OMX Nordic Exchange: AERO)
today announces the signing of an exclusive agreement with UK & Irish medical
device company Healthcare 21 Ltd for sales, marketing and distribution of
Aerocrine’s new airway inflammation monitor and test kit – NIOX VERO® – across
the UK and Ireland.
The agreement goes into effect on February 1, 2014 and gives Healthcare 21
exclusive rights for the sales marketing and distribution of Aerocrine’s new
instrument NIOX VERO® and test kits, used for diagnosing and monitoring patients
with asthma. The agreement also includes Healthcare 21 taking on the support,
sales and distribution for the already installed base of Aerocrine’s NIOX MINO®
devices across the UK & Irish market.
“As we continue the roll out of our new product, NIOX VERO® in the UK and
Ireland, we are delighted to be partnering with Healthcare 21, who is a leading
sales and marketing distributor with an existing and substantial UK & Irish
operation and proven track record of success in the respiratory and secondary
care market. This deal is part of Aerocrine’s strategy of substantially growing
the European business in a cost-efficient manner,” says David Plotts, Aerocrine
VP of International Sales & UK General Manager.

Aerocrine is committed to maintaining a substantial profile and direct presence
in the UK and Irish market to support development of FeNO guidelines, KOL
management, engagement with payers with particular focus and attention on the
primary care sector. Aerocrine will also directly continue to focus on
developing opportunities as a result of forthcoming NICE Guidance on FeNO and in
new healthcare environments such as pharmacy and occupational health.
Aerocrine offers versatile and easy-to-use monitoring devices for fractional
exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for
research and clinical applications are used for routine measurements in both
specialist and primary care clinics, and can be used to improve the management
of allergic airway inflammation, such as asthma.

“We are delighted to partner with Aerocrine in the UK and Ireland and we look
forward to supporting both existing and future customers whilst also working
with Aerocrine to establish FeNO testing as the standard of care method for
measuring allergic airway inflammation in our marketplaces” says David
Frederick, MD of Healthcare21
NIOX VERO® and NIOX MINO® offer added advantages for patient care, including
detecting allergic airway inflammation, determining the likelihood of
corticosteroid responsiveness, monitoring of airway inflammation to determine
the potential need for corticosteroid, and unmasking of otherwise unsuspected
non-adherence to corticosteroid therapy.

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368
0336
David Plotts, Vice President International Sales, Aerocrine Ltd, +44 7891 433239
David Frederick, Managing Director, Healthcare 21 +44 7585 552655

About Healthcare 21

The Healthcare 21 Group is a leading privately owned medtech sales and marketing
group of companies with an existing and substantial infrastructure in the UK &
Ireland. HC21 works in diversified fields and has long term distribution
agreements with leading multinational organizations.

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am on January 17, 2014.